Nagendran, Myura
McAuley, Daniel F.
Kruger, Peter S.
Papazian, Laurent
Truwit, Jonathon D.
Laffey, John G.
Thompson, B. Taylor
Clarke, Mike
Gordon, Anthony C.
Article History
Received: 25 September 2016
Accepted: 8 December 2016
First Online: 21 December 2016
Compliance with ethical standards
:
: There was no specific funding for this study. The HARP2 trial was supported by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership (08/99/08). The EME Programme is funded by the MRC and NIHR, with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health & Social Care (HSC) R&D Division, Public Health Agency in Northern Ireland. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NHS, NIHR or the Department of Health.
: DMcA reports Grants from the National Institute for Health Research, Efficacy and Mechanism Evaluation, the Health Research Board, Health and Social Care Research & Development office, the Intensive Care Society Ireland, and REVIVE to support the conduct of HARP-2. Outside the submitted work, DMcA reports personal fees from consultancy for GlaxoSmithKline (GSK), SOBI, Bayer, Boehringer Ingelheim and Peptinnovate. His institution has received grants from the NIHR and others, as well as funds from GSK for DMcA undertaking bronchoscopy as part of a clinical trial. In addition, DMcA also holds a patent for the use of a pharmacotherapy (not a statin) for treatment of ARDS awarded to Queen’s University Belfast. BTT reports Grants from the National Heart, Lung, and Blood Institute of the National Institute of Health. Outside the submitted work, BTT reports personal fees from consultancy for Alexion, Asahi Kasei, Boehringer Ingelheim, GlaxoSmithKline, and Regeneron. ACG reports, outside the submitted work, grants from the National Institute for Health Research that he has received speaker fees from Orion Corporation Orion Pharma and Amomed. He has consulted for Ferring Pharmaceuticals, Tenax Therapeutics and received Grant support from Orion Corporation Orion Pharma, Tenax Therapeutics and HCA International with funds paid to his institution. Other authors declare that they have no conflicts of interest.
Free to read: This content has been made available to all.